|
Variable
|
PFS
|
OS
|
DMFS
|
LRRFS
|
LRFS
|
RRFS
|
|---|
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
|---|
|
Age
|
0.948 (0.458–1.962)
|
0.885
|
1.365 (0.501–3.719)
|
0.543
|
0.505 (0.164–1.555)
|
0.234
|
0.750 (0.336–1.676)
|
0.483
|
0.662 (0.231–1.895)
|
0.442
|
1.097 (0.412–2.917)
|
0.853
|
|
Sex
|
0.866 (0.401–1.871)
|
0.715
|
0.506 (0.160–1.600)
|
0.246
|
0.652 (0.192–2.208)
|
0.492
|
0.568 (0.248–1.302)
|
0.182
|
0.595 (0.202–1.752)
|
0.346
|
0.489 (0.176–1.360)
|
0.171
|
|
T stage
|
2.733 (1.139–6.557)
|
0.024
|
4.523 (1.240–16.501)
|
0.022
|
11.418 (2.406–54.182)
|
0.002
|
1.616 (0.633–4.126)
|
0.315
|
1.473 (0.441–4.923)
|
0.529
|
2.985 (0.900–9.894)
|
0.074
|
|
N stage
|
2.070 (0.555–7.726)
|
0.279
|
2.852 (0.564–14.409)
|
0.205
|
8.385 (1.213–57.978)
|
0.031
|
1.380 (0.339–5.617)
|
0.653
|
2.054 (0.303–13.919)
|
0.461
|
2.979 (0.528–16.798)
|
0.216
|
|
Clinical stage
|
0.593 (0.240–1.463)
|
0.256
|
1.183 (0.369–3.790)
|
0.777
|
0.361 (0.086–1.515)
|
0.164
|
0.696 (0.285–1.697)
|
0.425
|
0.467 (0.132–1.651)
|
0.237
|
0.621 (0.192–2.008)
|
0.426
|
|
EBV DNA before first treatment
|
1.166 (0.553–2.459)
|
0.687
|
0.812 (0.287–2.295)
|
0.695
|
1.296 (0.287–0.423)
|
0.650
|
1.762 (0.770–4.033)
|
0.180
|
0.868 (0.300–2.510)
|
0.793
|
3.631 (1.013–13.019)
|
0.048
|
|
Preoperative EBV DNA
|
1.589 (0.768–3.290)
|
0.212
|
3.501 (1.075–11.398)
|
0.037
|
2.051 (0.688–6.119)
|
0.197
|
1.575 (0.732–3.389)
|
0.246
|
2.588 (0.926–7.234)
|
0.070
|
1.827 (0.684–4.882)
|
0.229
|
|
Treatment for NPC
|
1.341 (0.800–2.247)
|
0.266
|
1.621 (0.684–3.845)
|
0.273
|
3.367 (1.081–10.489)
|
0.036
|
1.120 (0.657–1.910)
|
0.677
|
0.840 (0.461–1.531)
|
0.569
|
2.184 (0.874–5.459)
|
0.095
|
- NPC nasopharyngeal carcinoma, PFS progression-free survival, OS overall survival, DMFS distant metastasis-free survival, LRRFS locoregional relapse-free survival, LRFS local relapse-free survival, RRFS regional relapse-free survival, HR hazard ratio, CI confidence interval
- All variables were transformed into categorical variables. HRs were calculated for age (≥ 45 vs. < 45 years), sex (male vs. female), T stage (3–4 vs. 1–2), N stage (3 vs. 1–2), clinical stage (IV vs. III vs. II), EBV DNA before first treatment (> 4000 vs. ≤ 4000 copies/mL), preoperative EBV DNA (> 0 vs. 0 copy/mL), and treatment for NPC (RT vs. CCRT vs. NAC + CCRT vs. CCRT + AC)
